hotspot -WSS

hotspot

author：focus 2025-10-01 21:09:27 - browse：887

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Bernie brings in new pharma CEOs to talk drug prices

hotspot

WSS

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

AI gets buy

Ancient Greek ideas underpin modern concepts of pregnancy

Johnson & Johnson sued for allegedly overpaying for workers' drugs

For AI in health care standards, federal regulators join with industry group

Unique patient identifier: Experts argue the benefits, pitfalls

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Jerome Adams on the need for new antivirals for Covid

Top private equity targets in 2023: cardiology, clinical trials, lasers

Sports medicine is finally prioritizing gender equality

He's 19 months old and has one of the world’s rarest diseases

Trump demands the U.S. pay no more for drugs than other countries … again

Ancient Greek ideas underpin modern concepts of pregnancy

Moonlake's readout produced a cash windfall. Risks remain

Why Novartis is going to walk from its acquisition of MorphoSys

In age of alternative facts, a scholarly course on calling out crap

Unique patient identifier: Experts argue the benefits, pitfalls

knowledge

The Biogen Aduhelm mess could happen again

Medicare Advantage plans can’t deny care with AI, CMS warns

Biden's 'march

Adopting new red light myopia treatments may be short

Adopting new red light myopia treatments may be short

Microsoft's Peter Lee: Generative AI could help doctors be more human

Wikipedia

hotspot

hotspot

focus